What label best describes this news article?
AstraZeneca in drive to slash costs Hostile environment prompts root and branch review. Exanta unlikely to win US approval in near future. By Stephen Foley. AstraZeneca, the UK #39;s number two pharmaceuticals company, has launched a  quot;root and branch  